Nano-X Imaging Ltd.

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NNOX is priced at $1.73, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NNOX's ROE is -0.47%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NNOX is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check BSX-PA's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ISRG has a market cap of 156.4B. Regarding current trading prices, NNOX is priced at $1.73, while ISRG trades at $441.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ISRG's P/E ratio is 53.79. In terms of profitability, NNOX's ROE is -0.47%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, NNOX is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ISRG's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ABT has a market cap of 154.7B. Regarding current trading prices, NNOX is priced at $1.73, while ABT trades at $88.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ABT's P/E ratio is 24.88. In terms of profitability, NNOX's ROE is -0.47%, compared to ABT's ROE of +0.12%. Regarding short-term risk, NNOX is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ABT's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, SYK has a market cap of 121.9B. Regarding current trading prices, NNOX is priced at $1.73, while SYK trades at $317.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas SYK's P/E ratio is 36.75. In terms of profitability, NNOX's ROE is -0.47%, compared to SYK's ROE of +0.15%. Regarding short-term risk, NNOX is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check SYK's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, MDT has a market cap of 100.9B. Regarding current trading prices, NNOX is priced at $1.73, while MDT trades at $78.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas MDT's P/E ratio is 21.95. In terms of profitability, NNOX's ROE is -0.47%, compared to MDT's ROE of +0.10%. Regarding short-term risk, NNOX is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check MDT's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, BSX has a market cap of 84.5B. Regarding current trading prices, NNOX is priced at $1.73, while BSX trades at $56.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas BSX's P/E ratio is 22.37. In terms of profitability, NNOX's ROE is -0.47%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NNOX is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check BSX's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, BRKRP has a market cap of 50B. Regarding current trading prices, NNOX is priced at $1.73, while BRKRP trades at $326.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas BRKRP's P/E ratio is N/A. In terms of profitability, NNOX's ROE is -0.47%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, NNOX is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check BRKRP's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, EW has a market cap of 47.3B. Regarding current trading prices, NNOX is priced at $1.73, while EW trades at $82.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas EW's P/E ratio is 44.42. In terms of profitability, NNOX's ROE is -0.47%, compared to EW's ROE of +0.11%. Regarding short-term risk, NNOX is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check EW's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, RMD has a market cap of 30.1B. Regarding current trading prices, NNOX is priced at $1.73, while RMD trades at $207.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas RMD's P/E ratio is 20.04. In terms of profitability, NNOX's ROE is -0.47%, compared to RMD's ROE of +0.24%. Regarding short-term risk, NNOX is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check RMD's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, DXCM has a market cap of 25.8B. Regarding current trading prices, NNOX is priced at $1.73, while DXCM trades at $66.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas DXCM's P/E ratio is 28.73. In terms of profitability, NNOX's ROE is -0.47%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, NNOX is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check DXCM's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, PHG has a market cap of 24.8B. Regarding current trading prices, NNOX is priced at $1.73, while PHG trades at $26.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas PHG's P/E ratio is 22.26. In terms of profitability, NNOX's ROE is -0.47%, compared to PHG's ROE of +0.09%. Regarding short-term risk, NNOX is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check PHG's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, STE has a market cap of 21B. Regarding current trading prices, NNOX is priced at $1.73, while STE trades at $214.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas STE's P/E ratio is 27.03. In terms of profitability, NNOX's ROE is -0.47%, compared to STE's ROE of +0.11%. Regarding short-term risk, NNOX is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check STE's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NNOX is priced at $1.73, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NNOX's ROE is -0.47%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NNOX is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ABMD's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ZBH has a market cap of 16.7B. Regarding current trading prices, NNOX is priced at $1.73, while ZBH trades at $86.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ZBH's P/E ratio is 22.30. In terms of profitability, NNOX's ROE is -0.47%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NNOX is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ZBH's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, SNN has a market cap of 13.2B. Regarding current trading prices, NNOX is priced at $1.73, while SNN trades at $30.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas SNN's P/E ratio is 21.57. In terms of profitability, NNOX's ROE is -0.47%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NNOX is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check SNN's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, NNOX is priced at $1.73, while PEN trades at $326.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas PEN's P/E ratio is 75.07. In terms of profitability, NNOX's ROE is -0.47%, compared to PEN's ROE of +0.12%. Regarding short-term risk, NNOX is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check PEN's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NNOX is priced at $1.73, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NNOX's ROE is -0.47%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NNOX is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check SWAV's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ALGN has a market cap of 11.1B. Regarding current trading prices, NNOX is priced at $1.73, while ALGN trades at $155.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ALGN's P/E ratio is 26.11. In terms of profitability, NNOX's ROE is -0.47%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, NNOX is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ALGN's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, GMED has a market cap of 10.8B. Regarding current trading prices, NNOX is priced at $1.73, while GMED trades at $79.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas GMED's P/E ratio is 18.67. In terms of profitability, NNOX's ROE is -0.47%, compared to GMED's ROE of +0.13%. Regarding short-term risk, NNOX is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check GMED's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, PODD has a market cap of 10.7B. Regarding current trading prices, NNOX is priced at $1.73, while PODD trades at $154.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas PODD's P/E ratio is 36.20. In terms of profitability, NNOX's ROE is -0.47%, compared to PODD's ROE of +0.21%. Regarding short-term risk, NNOX is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check PODD's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, NNOX is priced at $1.73, while MASI trades at $178.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas MASI's P/E ratio is 44.37. In terms of profitability, NNOX's ROE is -0.47%, compared to MASI's ROE of +0.09%. Regarding short-term risk, NNOX is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check MASI's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, GKOS has a market cap of 8.2B. Regarding current trading prices, NNOX is priced at $1.73, while GKOS trades at $139.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas GKOS's P/E ratio is -42.38. In terms of profitability, NNOX's ROE is -0.47%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, NNOX is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check GKOS's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, BIO has a market cap of 7.6B. Regarding current trading prices, NNOX is priced at $1.73, while BIO trades at $281.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas BIO's P/E ratio is 46.87. In terms of profitability, NNOX's ROE is -0.47%, compared to BIO's ROE of +0.02%. Regarding short-term risk, NNOX is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check BIO's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, BIO-B has a market cap of 7.2B. Regarding current trading prices, NNOX is priced at $1.73, while BIO-B trades at $267.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas BIO-B's P/E ratio is 44.57. In terms of profitability, NNOX's ROE is -0.47%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, NNOX is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check BIO-B's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, BRKR has a market cap of 6.5B. Regarding current trading prices, NNOX is priced at $1.73, while BRKR trades at $42.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas BRKR's P/E ratio is -177.46. In terms of profitability, NNOX's ROE is -0.47%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, NNOX is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check BRKR's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NNOX is priced at $1.73, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas NARI's P/E ratio is -59.24. In terms of profitability, NNOX's ROE is -0.47%, compared to NARI's ROE of -0.00%. Regarding short-term risk, NNOX is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check NARI's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, NNOX is priced at $1.73, while LIVN trades at $72.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas LIVN's P/E ratio is 37.20. In terms of profitability, NNOX's ROE is -0.47%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, NNOX is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check LIVN's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, NNOX is priced at $1.73, while IRTC trades at $113.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas IRTC's P/E ratio is -132.37. In terms of profitability, NNOX's ROE is -0.47%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, NNOX is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check IRTC's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NNOX is priced at $1.73, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NNOX's ROE is -0.47%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NNOX is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check AXNX's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, NNOX is priced at $1.73, while ITGR trades at $90.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ITGR's P/E ratio is 22.45. In terms of profitability, NNOX's ROE is -0.47%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, NNOX is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ITGR's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, TMDX has a market cap of 2.3B. Regarding current trading prices, NNOX is priced at $1.73, while TMDX trades at $66.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas TMDX's P/E ratio is 15.13. In terms of profitability, NNOX's ROE is -0.47%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, NNOX is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check TMDX's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, NNOX is priced at $1.73, while AXGN trades at $42.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas AXGN's P/E ratio is -66.70. In terms of profitability, NNOX's ROE is -0.47%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, NNOX is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check AXGN's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, NNOX is priced at $1.73, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NNOX's ROE is -0.47%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NNOX is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check NUVA's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, NNOX is priced at $1.73, while ESTA trades at $65.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ESTA's P/E ratio is -44.59. In terms of profitability, NNOX's ROE is -0.47%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, NNOX is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ESTA's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, NNOX is priced at $1.73, while UFPT trades at $217.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas UFPT's P/E ratio is 24.77. In terms of profitability, NNOX's ROE is -0.47%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NNOX is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check UFPT's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, NNOX is priced at $1.73, while ENOV trades at $25.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ENOV's P/E ratio is -1.30. In terms of profitability, NNOX's ROE is -0.47%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, NNOX is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ENOV's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, NNOX is priced at $1.73, while PRCT trades at $25.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas PRCT's P/E ratio is -14.16. In terms of profitability, NNOX's ROE is -0.47%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, NNOX is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check PRCT's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, NNOX is priced at $1.73, while AHCO trades at $10.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas AHCO's P/E ratio is -17.56. In terms of profitability, NNOX's ROE is -0.47%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, NNOX is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check AHCO's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NNOX is priced at $1.73, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NNOX's ROE is -0.47%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NNOX is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check HSKA's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, NNOX is priced at $1.73, while ATEC trades at $8.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ATEC's P/E ratio is -9.90. In terms of profitability, NNOX's ROE is -0.47%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, NNOX is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ATEC's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, NNOX is priced at $1.73, while INSP trades at $42.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas INSP's P/E ratio is 9.67. In terms of profitability, NNOX's ROE is -0.47%, compared to INSP's ROE of +0.18%. Regarding short-term risk, NNOX is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check INSP's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NNOX is priced at $1.73, while AVNS trades at $24.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas AVNS's P/E ratio is -15.47. In terms of profitability, NNOX's ROE is -0.47%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NNOX is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check AVNS's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, NNOX is priced at $1.73, while IART trades at $14.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas IART's P/E ratio is -2.22. In terms of profitability, NNOX's ROE is -0.47%, compared to IART's ROE of -0.48%. Regarding short-term risk, NNOX is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check IART's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NNOX is priced at $1.73, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas SILK's P/E ratio is -18.96. In terms of profitability, NNOX's ROE is -0.47%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NNOX is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check SILK's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, NNOX is priced at $1.73, while IRMD trades at $87.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas IRMD's P/E ratio is 47.74. In terms of profitability, NNOX's ROE is -0.47%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, NNOX is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check IRMD's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, NNOX is priced at $1.73, while AORT trades at $22.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas AORT's P/E ratio is 90.94. In terms of profitability, NNOX's ROE is -0.47%, compared to AORT's ROE of +0.03%. Regarding short-term risk, NNOX is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for NNOX.Check AORT's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NNOX is priced at $1.73, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas FNA's P/E ratio is -19.83. In terms of profitability, NNOX's ROE is -0.47%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NNOX is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check FNA's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, NNOX is priced at $1.73, while CNMD trades at $36.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas CNMD's P/E ratio is 20.43. In terms of profitability, NNOX's ROE is -0.47%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, NNOX is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check CNMD's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, BFLY has a market cap of 1.1B. Regarding current trading prices, NNOX is priced at $1.73, while BFLY trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas BFLY's P/E ratio is -13.68. In terms of profitability, NNOX's ROE is -0.47%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, NNOX is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for NNOX.Check BFLY's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, TNDM has a market cap of 949.8M. Regarding current trading prices, NNOX is priced at $1.73, while TNDM trades at $13.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas TNDM's P/E ratio is -10.12. In terms of profitability, NNOX's ROE is -0.47%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, NNOX is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check TNDM's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, INMD has a market cap of 885.1M. Regarding current trading prices, NNOX is priced at $1.73, while INMD trades at $13.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas INMD's P/E ratio is 10.35. In terms of profitability, NNOX's ROE is -0.47%, compared to INMD's ROE of +0.13%. Regarding short-term risk, NNOX is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check INMD's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NNOX is priced at $1.73, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas CSII's P/E ratio is -20.83. In terms of profitability, NNOX's ROE is -0.47%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NNOX is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check CSII's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, SSII has a market cap of 790.5M. Regarding current trading prices, NNOX is priced at $1.73, while SSII trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas SSII's P/E ratio is -79.00. In terms of profitability, NNOX's ROE is -0.47%, compared to SSII's ROE of -0.23%. Regarding short-term risk, NNOX is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check SSII's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, NNOX is priced at $1.73, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas CRY's P/E ratio is 425.71. In terms of profitability, NNOX's ROE is -0.47%, compared to CRY's ROE of +0.03%. Regarding short-term risk, NNOX is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check CRY's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, BVS has a market cap of 722.2M. Regarding current trading prices, NNOX is priced at $1.73, while BVS trades at $10.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas BVS's P/E ratio is 26.00. In terms of profitability, NNOX's ROE is -0.47%, compared to BVS's ROE of +0.16%. Regarding short-term risk, NNOX is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check BVS's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, LMRI has a market cap of 672.6M. Regarding current trading prices, NNOX is priced at $1.73, while LMRI trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas LMRI's P/E ratio is -17.95. In terms of profitability, NNOX's ROE is -0.47%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, NNOX is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check LMRI's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, SIBN has a market cap of 658.1M. Regarding current trading prices, NNOX is priced at $1.73, while SIBN trades at $14.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas SIBN's P/E ratio is -38.05. In terms of profitability, NNOX's ROE is -0.47%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, NNOX is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check SIBN's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, CBLL has a market cap of 643.5M. Regarding current trading prices, NNOX is priced at $1.73, while CBLL trades at $16.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas CBLL's P/E ratio is -10.47. In terms of profitability, NNOX's ROE is -0.47%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, NNOX is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check CBLL's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NNOX is priced at $1.73, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NNOX's ROE is -0.47%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, NNOX is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check SRDX's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, BWAY has a market cap of 584M. Regarding current trading prices, NNOX is priced at $1.73, while BWAY trades at $14.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas BWAY's P/E ratio is 82.72. In terms of profitability, NNOX's ROE is -0.47%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, NNOX is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check BWAY's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NNOX is priced at $1.73, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas APEN's P/E ratio is -9.43. In terms of profitability, NNOX's ROE is -0.47%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NNOX is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check APEN's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, TCMD has a market cap of 547.2M. Regarding current trading prices, NNOX is priced at $1.73, while TCMD trades at $24.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas TCMD's P/E ratio is 27.89. In terms of profitability, NNOX's ROE is -0.47%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, NNOX is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check TCMD's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, CERS has a market cap of 541M. Regarding current trading prices, NNOX is priced at $1.73, while CERS trades at $2.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas CERS's P/E ratio is -54.00. In terms of profitability, NNOX's ROE is -0.47%, compared to CERS's ROE of -0.15%. Regarding short-term risk, NNOX is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for NNOX.Check CERS's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, NPCE has a market cap of 540.4M. Regarding current trading prices, NNOX is priced at $1.73, while NPCE trades at $15.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas NPCE's P/E ratio is -24.38. In terms of profitability, NNOX's ROE is -0.47%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, NNOX is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check NPCE's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NNOX is priced at $1.73, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NNOX's ROE is -0.47%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, NNOX is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ZIMV's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, OFIX has a market cap of 488.7M. Regarding current trading prices, NNOX is priced at $1.73, while OFIX trades at $12.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas OFIX's P/E ratio is -8.06. In terms of profitability, NNOX's ROE is -0.47%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, NNOX is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check OFIX's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, KIDS has a market cap of 468.2M. Regarding current trading prices, NNOX is priced at $1.73, while KIDS trades at $18.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas KIDS's P/E ratio is -10.85. In terms of profitability, NNOX's ROE is -0.47%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, NNOX is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check KIDS's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, CTKB has a market cap of 461M. Regarding current trading prices, NNOX is priced at $1.73, while CTKB trades at $3.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas CTKB's P/E ratio is -6.16. In terms of profitability, NNOX's ROE is -0.47%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, NNOX is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check CTKB's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, VREX has a market cap of 392.4M. Regarding current trading prices, NNOX is priced at $1.73, while VREX trades at $9.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas VREX's P/E ratio is -4.66. In terms of profitability, NNOX's ROE is -0.47%, compared to VREX's ROE of -0.18%. Regarding short-term risk, NNOX is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check VREX's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, LAB has a market cap of 390.4M. Regarding current trading prices, NNOX is priced at $1.73, while LAB trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas LAB's P/E ratio is -7.69. In terms of profitability, NNOX's ROE is -0.47%, compared to LAB's ROE of -0.21%. Regarding short-term risk, NNOX is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check LAB's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, DCTH has a market cap of 374.6M. Regarding current trading prices, NNOX is priced at $1.73, while DCTH trades at $10.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas DCTH's P/E ratio is 1085.00. In terms of profitability, NNOX's ROE is -0.47%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, NNOX is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check DCTH's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, VMD has a market cap of 368.4M. Regarding current trading prices, NNOX is priced at $1.73, while VMD trades at $9.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas VMD's P/E ratio is 25.97. In terms of profitability, NNOX's ROE is -0.47%, compared to VMD's ROE of +0.11%. Regarding short-term risk, NNOX is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check VMD's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, PACB has a market cap of 357.2M. Regarding current trading prices, NNOX is priced at $1.73, while PACB trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas PACB's P/E ratio is -2.80. In terms of profitability, NNOX's ROE is -0.47%, compared to PACB's ROE of -4.88%. Regarding short-term risk, NNOX is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check PACB's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, CLPT has a market cap of 335M. Regarding current trading prices, NNOX is priced at $1.73, while CLPT trades at $11.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas CLPT's P/E ratio is -11.17. In terms of profitability, NNOX's ROE is -0.47%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, NNOX is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check CLPT's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ELMD has a market cap of 317.4M. Regarding current trading prices, NNOX is priced at $1.73, while ELMD trades at $38.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ELMD's P/E ratio is 32.76. In terms of profitability, NNOX's ROE is -0.47%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, NNOX is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ELMD's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NNOX is priced at $1.73, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NNOX's ROE is -0.47%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, NNOX is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check SMLR's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, AVR has a market cap of 282.9M. Regarding current trading prices, NNOX is priced at $1.73, while AVR trades at $7.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas AVR's P/E ratio is -3.46. In terms of profitability, NNOX's ROE is -0.47%, compared to AVR's ROE of -1.24%. Regarding short-term risk, NNOX is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check AVR's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, CATX has a market cap of 280.8M. Regarding current trading prices, NNOX is priced at $1.73, while CATX trades at $3.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas CATX's P/E ratio is -2.58. In terms of profitability, NNOX's ROE is -0.47%, compared to CATX's ROE of -0.42%. Regarding short-term risk, NNOX is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check CATX's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, SGHT has a market cap of 256.8M. Regarding current trading prices, NNOX is priced at $1.73, while SGHT trades at $4.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas SGHT's P/E ratio is -6.74. In terms of profitability, NNOX's ROE is -0.47%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, NNOX is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check SGHT's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, MASS has a market cap of 256.4M. Regarding current trading prices, NNOX is priced at $1.73, while MASS trades at $6.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas MASS's P/E ratio is -6.99. In terms of profitability, NNOX's ROE is -0.47%, compared to MASS's ROE of -0.26%. Regarding short-term risk, NNOX is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check MASS's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, PMI has a market cap of 255.1M. Regarding current trading prices, NNOX is priced at $1.73, while PMI trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas PMI's P/E ratio is -0.22. In terms of profitability, NNOX's ROE is -0.47%, compared to PMI's ROE of +4.99%. Regarding short-term risk, NNOX is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for NNOX.Check PMI's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, RXST has a market cap of 246.3M. Regarding current trading prices, NNOX is priced at $1.73, while RXST trades at $5.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas RXST's P/E ratio is -5.27. In terms of profitability, NNOX's ROE is -0.47%, compared to RXST's ROE of -0.17%. Regarding short-term risk, NNOX is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check RXST's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NNOX is priced at $1.73, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas MGRM's P/E ratio is -11.11. In terms of profitability, NNOX's ROE is -0.47%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, NNOX is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check MGRM's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, SENS has a market cap of 231.5M. Regarding current trading prices, NNOX is priced at $1.73, while SENS trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas SENS's P/E ratio is -2.81. In terms of profitability, NNOX's ROE is -0.47%, compared to SENS's ROE of -1.30%. Regarding short-term risk, NNOX is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check SENS's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NNOX is priced at $1.73, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NNOX's ROE is -0.47%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NNOX is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check NVRO's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, NNOX is priced at $1.73, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas EYES's P/E ratio is N/A. In terms of profitability, NNOX's ROE is -0.47%, compared to EYES's ROE of -2.64%. Regarding short-term risk, NNOX is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check EYES's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, PROF has a market cap of 203.6M. Regarding current trading prices, NNOX is priced at $1.73, while PROF trades at $6.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas PROF's P/E ratio is -5.43. In terms of profitability, NNOX's ROE is -0.47%, compared to PROF's ROE of -0.71%. Regarding short-term risk, NNOX is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check PROF's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, ANIK has a market cap of 197.3M. Regarding current trading prices, NNOX is priced at $1.73, while ANIK trades at $14.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas ANIK's P/E ratio is -18.77. In terms of profitability, NNOX's ROE is -0.47%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, NNOX is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check ANIK's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NNOX is priced at $1.73, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NNOX's ROE is -0.47%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, NNOX is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for NNOX.Check BSGM's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NNOX is priced at $1.73, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NNOX's ROE is -0.47%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NNOX is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for NNOX.Check MDGS's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, TMCI has a market cap of 176.5M. Regarding current trading prices, NNOX is priced at $1.73, while TMCI trades at $2.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas TMCI's P/E ratio is -2.83. In terms of profitability, NNOX's ROE is -0.47%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, NNOX is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for NNOX.Check TMCI's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, INGN has a market cap of 174.6M. Regarding current trading prices, NNOX is priced at $1.73, while INGN trades at $6.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas INGN's P/E ratio is -7.09. In terms of profitability, NNOX's ROE is -0.47%, compared to INGN's ROE of -0.13%. Regarding short-term risk, NNOX is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check INGN's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, APYX has a market cap of 165M. Regarding current trading prices, NNOX is priced at $1.73, while APYX trades at $3.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas APYX's P/E ratio is -17.91. In terms of profitability, NNOX's ROE is -0.47%, compared to APYX's ROE of -0.91%. Regarding short-term risk, NNOX is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check APYX's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NNOX is priced at $1.73, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NNOX's ROE is -0.47%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, NNOX is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check QIPT's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, EDAP has a market cap of 161.9M. Regarding current trading prices, NNOX is priced at $1.73, while EDAP trades at $4.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas EDAP's P/E ratio is -5.27. In terms of profitability, NNOX's ROE is -0.47%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, NNOX is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check EDAP's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, CVRX has a market cap of 158.8M. Regarding current trading prices, NNOX is priced at $1.73, while CVRX trades at $6.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas CVRX's P/E ratio is -2.99. In terms of profitability, NNOX's ROE is -0.47%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, NNOX is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check CVRX's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, SNWV has a market cap of 143.5M. Regarding current trading prices, NNOX is priced at $1.73, while SNWV trades at $16.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas SNWV's P/E ratio is 17.39. In terms of profitability, NNOX's ROE is -0.47%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, NNOX is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check SNWV's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, QTI has a market cap of 142.2M. Regarding current trading prices, NNOX is priced at $1.73, while QTI trades at $5.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas QTI's P/E ratio is -2.61. In terms of profitability, NNOX's ROE is -0.47%, compared to QTI's ROE of -63.30%. Regarding short-term risk, NNOX is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for NNOX.Check QTI's competition here

NNOX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NNOX stands at 120.4M. In comparison, TLSI has a market cap of 119.4M. Regarding current trading prices, NNOX is priced at $1.73, while TLSI trades at $3.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NNOX currently has a P/E ratio of -1.49, whereas TLSI's P/E ratio is -2.22. In terms of profitability, NNOX's ROE is -0.47%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, NNOX is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for NNOX.Check TLSI's competition here